



PATENT

Attorney Docket No.: A-67501/DJB/TAL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<u>In re</u> application of:)	Examiner: Harris, A.
)	
GOETZL et al.)	Group Art Unit: 1643
)	
Serial No. 09/274,752)	
)	
Filed: March 23, 1999)	
)	
For: HUMAN POLYPEPTIDE)	
RECEPTORS FOR LYSO-)	
PHOSPHOLIPIDS AND SPHING-)	
OLIPIDS AND NUCLEIC ACIDS)	
ENCODING THE SAME)	
_____)	

CERTIFICATE OF MAILING

I hereby certify that this correspondence, including listed enclosures, is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231 on:

Dated: 4-4-00
Signed: Christine P. Peters
Christine P. Peters

TRANSMITTAL OF RESPONSE TO COMMUNICATION
AND NOTICE TO COMPLY

BOX SEQUENCE LISTING
Assistant Commissioner
for Patents
Washington, DC 20231

Sir:

In response to the Office Communication and accompanying Notice
to Comply With Requirements for Patent Applications Containing Nucleotide

Serial No.: 09/274,752
Filed: March 23, 1999

Sequence and/or Amino Acid Sequence Disclosures dated March 30, 2000 enclosed
are the following:

1. Replacement Computer readable form of Sequence Listing;
2. Preliminary Amendment;
3. Copy of Notice to Comply;

The Commissioner is authorized to charge any additional fees which
may be required, or credit any overpayment to Deposit Account No. 06-1300 (Our
Order No. A-67501/DJB/TAL).

A duplicate copy of this sheet is enclosed..

Respectfully submitted,

FLEHR HOHBACH TEST
ALBRITTON & HERBERT LLP



Todd A. Lorenz
Reg. 39,754

Four Embarcadero Center
Suite 3400
San Francisco, CA 94111-4187
Telephone: (415) 781-1989
1014439

RECEIVED

NOV 06 2000

TECH CENTER 1600/2900

UTILITY PATENT (MISCELLANEOUS)

Rec'd. in the U.S. Patent and Trademark Office on the date stamped hereon via
Certificate of Mail:

Atty. Docket # A-67501/DJB/TAL

Applicant: GOETZL et al.


Ser. No.: 09/274,752

Filed: March 23, 1999

Title:

HUMAN POLYPEPTIDE RECEPTORS FOR LYSOPHOSPHOLIPIDS AND
SPHINGOLIPIDS AND NUCLEIC ACIDS ENCODING THE SAME

- ▶ Computer readable form of Sequence Listing (Disc)
- ▶ Preliminary Amendment
- ▶ Copy of Nice to Comply



Due Date: _____

Certificate of Mailing: _____

4-4-00
AP



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231


DK

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

09/274,752 03/23/99 GOETZL

E A-67501/DJB/

HM12/0330
FLEHR HOEBACH TEST ALBRITTON & HERBERT
FOUR EMBARCADERO CENTER
SUITE 3400
SAN FRANCISCO CA 94111-4187



EXAMINER

HARRIS, A

ART UNIT	PAPER NUMBER
----------	--------------

1642

DATE MAILED:

03/30/00

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

File A-67501 Atty DJB, TAL
Due Date 4/30/2000
Type mo. O.A. Refs 2



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

DEA/FCE-1994

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.

EXAMINER	
ART UNIT	PAPER NUMBER

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application

Commissioner of Patents

1. The reply filed October 12, 1999 is not fully responsive to the communication mailed August 11, 1999 for the reason(s) set forth on the enclosed copy of the Notice To Comply. Since the above-mentioned reply appears to be *bona fide*, applicant is given a TIME PERIOD of **ONE (1) MONTH** or **THIRTY (30) DAYS**, from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME LIMIT MAY BE GRANTED UNDER 37 CAR 1.136(a). Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.
2. Any inquiry concerning this communication should be directed to Examiner Alana M. Harris, Art Unit 1642, whose telephone number is (703)306-5880.
3. Any questions regarding compliance with the sequence rules requirements specifically should be directed to the departments listed at the bottom of the Notice to Comply.

Alana M. Harris, Ph.D.
Patent Examiner
Group 1642

NANCY A. JOHNSON, PH.D
PRIMARY EXAMINER



Application No.: 09/274,752

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- ☒ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: _____

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☐ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212


For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

A. Harris

43


BIOTECHNOLOGY
SYSTEMS
BRANCH



CRF Diskette Problem Report

The Scientific and Technical Information Center (STIC) experienced a problem when processing the following CRF diskette:

Application Serial Number: 09/274,752
Filing Date: 2/23/99
Classification: 435
Date Processed by STIC: 10/25/99



Point-of-Contact/Telephone No.: Mark Spencer 703 - 308 - 4212

Nature of Problem:

The diskette was:

- ☐ Damaged
- ☐ Unreadable
- ☐ Blank (no files present on diskette)
- ☒ Contained an empty file (filename present, but no bytes in file)
- ☒ A computer virus was detected on the diskette. The STIC will not process the diskette through the Data Capture System.

Name of virus: Anti EXE boot virus

- ☐ The Sequence Listing was not saved in ASCII (DOS) text.
- ☐ The diskette contained an error that disrupted normal processing:

Revision of Patent and Trademark Fees for Fiscal Year 2000
In view of the American Inventors Protection Act of 1999, Public Law 106-113

The following amendments to the fee amounts in 37 CFR 1.16, 1.20, and 1.492 shown below will be effective on December 29, 1999:

Patent Fees:

37 CFR

Sec.	Description	Current Fee Amount	New Fee Amount (Effective 12/29/99)
1.16(a)	Basic filing fee – Utility	\$760	\$690
1.16(a)	Basic filing fee – Utility (Small Entity)	\$380	\$345
1.16(a)	Basic filing fee – Utility (CPA)	\$760	\$690
1.16(a)	Basic filing fee – Utility (CPA) (Small Entity)	\$380	\$345
1.16(h)	Reissue filing fee	\$760	\$690
1.16(h)	Reissue filing fee (Small Entity)	\$380	\$345
1.16(h)	Reissue filing fee (CPA)	\$760	\$690
1.16(h)	Reissue filing fee (CPA) (Small Entity)	\$380	\$345
1.20(e)	Maintenance fee – due at 3.5 years	\$940	\$830
1.20(e)	Maintenance fee – due at 3.5 years (Small Entity)	\$470	\$415
1.492(a)(2)	ISA - U.S.	\$760	\$690
1.492(a)(2)	ISA - U.S. (Small Entity)	\$380	\$345

The following amendments to the fee amounts in 37 CFR 1.17 and 2.6 shown below will be effective on January 10, 2000:

Patent Fees:

37 CFR

Sec.	Description	Current Fee Amount	New Fee Amount (Effective 1/10/00)
1.17(r)	Filing a submission after final rejection (1.129(a))	\$760	\$690
1.17(r)	Filing a submission after final rejection (1.129(a)) (Small Entity)	\$380	\$345
1.17(s)	Per additional invention to be examined (1.129(b))	\$760	\$690
1.17(s)	Per additional invention to be examined (1.129(b)) (Small Entity)	\$380	\$345

Trademark Fees:

37 CFR

Sec.	Description	Current Fee Amount	New Fee Amount (Effective 1/10/00)
2.6(a)(1)	Application for registration, per class	\$245	\$325
2.6(a)(4)	Extension for filing Statement of Use, per class	\$100	\$150
2.6(a)(5)	Application for renewal, per class	\$300	\$400
2.6(a)(13)	Filing section 15 affidavit, per class	\$100	\$200
2.6(a)(16)	Petition for cancellation, per class	\$200	\$300
2.6(a)(17)	Notice of opposition, per class	\$200	\$300

Patent and trademark customers are responsible for paying the correct fee amounts. We advise our customers to refer to the official PTO Web site at www.uspto.gov or contact the PTO General Information Services Division at (703) 308-4357 or (800) PTO-9199 for the most current fee amounts and information.

